

FORM PTO-1449 (REV. 7-99) INFORMATION DISCLOSURE STATEMENT (To be filled out by applicant or agent) (Include all sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.465C3	APPLICATION NO. 09/685,830
	APPLICANTS Alexander Gaiger and Martin A. Cheever		
	FILING DATE October 9, 2000	GROUP ART UNIT	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RBS	AA	5,350,840	09/27/94	Call et al.	536	23.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
RBS	AB	WO99/58135	11/18/99	PCT WO	—	—
	AC	WO95/29995	11/09/95	PCT WO	—	—
	AD	WO95/06725	03/09/95	PCT WO	—	—
	AE	WO 91/07509	05/30/91	PCT WO	—	—

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

RBS	AF	Adachi et al., "Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)," <i>Oncogene</i> 13: 2197-2203, 1996.
	AG	Algar et al., "A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines," <i>Oncogene</i> 12: 1005-1014, 1996.
	AH	Armstrong et al., "The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo," <i>Mechanisms of Development</i> 40: 85-97, 1992.
	AI	Bellantuono et al., "Selective elimination of leukemic progenitors by allorestricted CTL specific for WILMS Tumor Antigen-1 (WT-1)," <i>Blood</i> , 94(10):532A-533A, November 15, 1999.
	AJ	Bergmann et al., "High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome," <i>Blood</i> 90(3): 1217-1225, 1997.
	AK	Bergmann et al., "Wilms Tumor Gene Expression in Acute Myeloid Leukemias," <i>Leukemia and Lymphoma</i> 25: 435-443, 1997.
	AL	Brenner et al., "RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors," <i>Oncogene</i> 7: 1431-1433, 1992.

EXAMINER 	DATE CONSIDERED 4/3/2002
---	-----------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICESIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use second sheet if necessary)ATTY. DOCKET NO.
210121.465C3APPLICATION NO.
09/685,830APPLICANTS
Alexander Gaiger et al.FILING DATE
October 9, 2000EXHIBIT ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
B3	AA	2003/0039635	02/27/03	Gaiger et al.	424	93.2	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AI					
	AJ					
	AK					
	AL					
	AM					

OTHER ART (Including Author, Title, Date, Periodical Pages, Etc.)

B3	AN	Grosenbach, D.W. et al., "Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects," <i>Cancer Research</i> 61: 4497-4505, June 1, 2001.
	AO	Hale, R.S. et al., "Codon Optimization of the Gene Encoding a Domain from Human Type 1 Neurofibromin Protein Results in a Threefold Improvement in Expression Level in <i>Escherichia coli</i> ," <i>Protein Expression and Purification</i> 12: 185-188, 1998.
	AP	Oka, Y. et al., "Cancer Immunotherapy Targeting Wilms' Tumor Gene WT1 Product," <i>The Journal of Immunology</i> 164: 1873-1880, 2000.
	AQ	Oka, Y. et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (<i>WT1</i>) product," <i>Immunogenetics</i> 51: 99-107, 2000.

EXAMINER

DATE CONSIDERED

9/16/07

* EXAMINER: Initial if reference considered, whether or not criteria is in accordance with MPEP 609. Draw line through criteria if not in accordance and not considered. Include copy of this form with each communication to applicant(s).